Catalog No.
Product Name
Application
Product Information
Citations
-
PD-1/PD-L1 Inhibitor
Human PD-L1 inhibitor II is a potent inhibitor of the PD-1/PD-L1 interaction, playing a crucial role in immune checkpoint regulation. This compound exhibits significant anti-cancer activity by enhancing T-cell responses against tumor cells. It is primarily used in research applications focused on cancer immunotherapy and understanding the mechanisms of immune evasion. -
PD-L1 PROTAC Degrader
PROTAC PD-L1 degrader-2 is a selective degrader targeting PD-L1. It demonstrates a potent inhibitory effect with an IC50 of 197.4 nM and a binding affinity characterized by a Kd of 301 nM. This compound facilitates the internalization and subsequent degradation of PD-L1 through both proteasomal and lysosomal pathways, thereby enhancing immune system activation. Its efficacy has been validated in MC38 C57BL/6 mouse models, underscoring its potential for antitumor applications. -
PD-1/PD-L1 Inhibitor
PD-1/PD-L1-IN-36 is an inhibitor of the PD-1/PD-L1 complex, exhibiting an IC50 of 15 nM. This compound plays a crucial role in cancer immunotherapy research by blocking the interaction between PD-1 and PD-L1, which is instrumental in tumor immune evasion. Its application in studies may enhance understanding of immune checkpoint mechanisms and the development of novel therapeutic strategies in oncology. -
PD-1/PD-L1Inhibitor
SCL-1 is an orally active inhibitor of the PD-1/PD-L1 pathway, effectively blocking the interaction between PD-1 and PD-L1. This compound enhances the proliferation of T cells, B cells, and natural killer cells, contributing to robust antitumor activity. SCL-1 mediates tumor growth inhibition through the induction of effector T cells within the tumor environment and by upregulating long non-coding RNAs that act as neoantigens, facilitating cytotoxic T lymphocyte activation. This reagent is valuable for cancer research, particularly in studies focused on triple-negative breast cancer. -
Anti-inflammatory Agent
Sulindac sodium is an orally active nonsteroidal anti-inflammatory agent that exerts its effects through the inhibition of cyclooxygenase enzymes, leading to decreased prostaglandin synthesis. This compound demonstrates significant anti-inflammatory and immunomodulatory properties, making it valuable for investigating conditions such as arthritis, gout, and various cancers including colorectal cancer (CRC) and lung cancer. Its diverse mechanisms of action and potential therapeutic applications contribute to its utility in cancer and inflammation research. -
PD-1/PD-L1 Inhibitor
PD-1/PD-L1-IN 5 is a potent inhibitor of the PD-1/PD-L1 protein-protein interaction, demonstrating an IC50 of ≤100 nM. This compound is valuable for studies investigating immune checkpoint inhibition and its role in enhancing anti-tumor immunity. Researchers can utilize this reagent in various applications related to cancer immunotherapy and the modulation of immune responses. -
PD-1/PD-L1 Inhibitor
PD-1/PD-L1-IN 5 TFA is a potent inhibitor of the PD-1/PD-L1 protein-protein interaction, with an IC50 of ≤100 nM. This compound is beneficial for research applications focused on immune checkpoint modulation, particularly in the context of cancer immunotherapy. By blocking the PD-1/PD-L1 pathway, it aids in the investigation of T-cell activation and tumor immune evasion mechanisms. -
hPD-1 Ligand
Human PD-L1 inhibitor I is a peptide ligand targeting human PD-1 ligand with a binding affinity (KD) of 3.39 μM. This compound is designed to disrupt the interaction between hPD-L1 and hPD-1, making it a valuable tool for studying immune checkpoint inhibition. Its applications include investigating mechanisms of immune evasion in cancer and exploring potential therapeutic strategies for enhancing anti-tumor immunity. -
PD-1/PD-L1 Inhibitor
LLW-018 is a potent inhibitor of the PD-1/PD-L1 interaction, demonstrating an IC50 value of 2.61 nM. This compound effectively disrupts the PD-1/PD-L1 pathway, showing an IC50 of 0.88 μM in cell-based assays. LLW-018 holds significant potential for applications in immunotherapy research, particularly in the development of cancer treatments that target immune checkpoint pathways. -
PD-1/PD-L1 inhibitor
PD-1/PD-L1-IN 6 is a potent inhibitor of the PD-1/PD-L1 interaction, demonstrating an IC50 value of 132.8 nM. This compound exhibits significant immunoregulatory activity, notably enhancing interferon-γ secretion in a Hep3B/OS-8/hPD-L1 and CD3 T cell co-culture model, while exhibiting minimal toxicity. Additionally, PD-1/PD-L1-IN 6 is effective in restoring immune responses in T cell-tumor co-culture models, making it a valuable reagent for immunotherapy research and studies related to cancer immunology. -
PD-1/PD-L1 Inhibitor
PD-1/PD-L1-IN-32 is a potent inhibitor of the PD-1/PD-L1 pathway, exhibiting an IC50 of 2.4 nM. This compound demonstrates significant anticancer activity by effectively inhibiting tumor growth in a humanized mouse model expressing PD-L1. Importantly, PD-1/PD-L1-IN-32 exhibits limited toxicity on normal mouse tissues, making it a valuable tool for cancer research and therapeutic applications targeting immune checkpoint pathways. -
PD-L1 Inhibitor
BMS-1233 is a potent inhibitor of programmed cell death-ligand 1 (PD-L1) with an IC50 of 14.5 nM. This compound promotes cytotoxicity in HepG2 cells within a Jurkat T cell and HepG2 co-culture model, demonstrating significant antitumor activity against melanoma in in vivo mouse models. BMS-1233 is suitable for research applications focused on cancer immunotherapy and the modulation of immune checkpoint pathways. -
PD-L1 Ligand
2-Methylbiphenyl-oxadiazole-NH-Ph-CHO functions as a ligand for PD-L1, playing a crucial role in the development of AUTAC PD-L1 degrader-3. This compound is essential for facilitating targeted degradation of PD-L1, making it a valuable tool in cancer immunotherapy research and studies focusing on the modulation of immune checkpoints. Additionally, it can be utilized in the synthesis of AUTACs for advanced therapeutic applications. -
PD-L1/NAMPT Inhibitor
PD-L1/Nampt-IN-1 is a dual inhibitor targeting PD-L1 and NAMPT (nicotinamide phosphoribosyltransferase) with IC50 values of 63 nM and 582 nM, respectively. This compound exhibits cross-species affinity with comparable KD values for human PD-L1 (52.6 nM) and mouse PD-L1 (49.1 nM). PD-L1/Nampt-IN-1 facilitates tumor growth inhibition by enhancing the tumor immune microenvironment, making it a valuable tool for research in melanoma studies. -
PD-1/PD-L1 Inhibitor
LP23 is a potent non-arylmethylamine inhibitor of the PD-1/PD-L1 axis, exhibiting an IC50 of 16.7 nM. It effectively restores immune cell function in HepG2 and Jurkat T cell assays and promotes cell death in HepG2 cancer cells. In vivo studies demonstrate its significant anti-tumor activity in the B16-F10 tumor model, achieving a tumor growth inhibition of 88.6% at a dose of 30 mg/kg. This compound serves as a valuable tool for cancer immunotherapy research and the investigation of immune checkpoint pathways. -
PD-L1 Inhibitor
PD-L1-IN-5 is a potent inhibitor of programmed death-ligand 1 (PD-L1), exhibiting an IC50 value of 785.6 nM. This compound demonstrates significant anti-tumor activity in vivo, making it a valuable tool for cancer research. PD-L1-IN-5 is utilized in studies focusing on immune checkpoint regulation and therapeutic strategies aimed at enhancing anti-tumor immunity. -
PD-L1
Cadapersen is an antisense oligonucleotide that selectively induces the degradation of PD-L1 mRNA. By inhibiting PD-L1 expression, this reagent serves as a valuable tool in the investigation of immune responses and mechanisms underlying chronic hepatitis B (CHB). Its application in research enhances the understanding of immune checkpoint regulation, facilitating studies geared towards novel therapeutic strategies. -
PD-1/PD-L1 Inhibitor
PD-1/PD-L1-IN-26 is a potent inhibitor of the programmed death-1 (PD-1)/programmed death-ligand 1 (PD-L1) pathway, exhibiting an IC50 of 0.0380 μM. This compound enhances the immune microenvironment by facilitating the infiltration of CD4+ T cells into tumor tissues. PD-1/PD-L1-IN-26 is valuable for research applications focused on cancer immunotherapy and the modulation of immune responses in tumor biology. -
PD-1/PD-L1 Inhibitor
PD-1/PD-L1-IN-59 is a PD-1/PD-L1 inhibitor with an IC50 value of 183 nM. This compound is instrumental in the investigation of immune checkpoint regulation and has significant potential for research applications in triple-negative breast cancer (TNBC) therapies. By blocking the PD-1/PD-L1 interaction, it fosters immune response against tumor cells and facilitates the exploration of novel immunotherapeutic strategies. -
PD-L1 Inhibitor
PD-1/PD-L1-IN-60 is an inhibitor of PD-L1, a key checkpoint protein involved in immune evasion of tumors. This compound demonstrates significant anti-tumor activity in preclinical models, particularly within melanoma and lung cancer contexts where PD-L1 expression is elevated. PD-1/PD-L1-IN-60 is suitable for research applications focused on immunotherapy, tumor immune microenvironment studies, and the evaluation of therapeutic strategies targeting PD-L1. -
PD-1/PD-L1 Inhibitor
PD-1/PD-L1-IN-20 is a small-molecule inhibitor targeting the PD-1/PD-L1 protein-protein interaction, demonstrating an IC50 of 5.29 nM. This compound effectively disrupts the PD-1/PD-L1 pathway, making it a valuable tool for research in oncology, infectious diseases, and autoimmune disorders. Its ability to modulate immune checkpoint proteins provides significant insights into therapeutic strategies for enhancing anti-tumor immunity. -
PD-L1 Enhancer
Ir-UA is an iridium(III) complex derived from usnic acid that serves as a PD-L1 enhancer. This compound promotes the expression of PD-L1 by specifically modulating the associated transcription factors, thus facilitating the conversion of "cold tumors" into "hot tumors." Ir-UA is valuable in cancer research, particularly in studies focused on immunotherapy and tumor microenvironment modulation. -
PD-L1/PD-1 Inhibitor
PD-L1/PD-1-IN-1 is a potent inhibitor of the PD-L1/PD-1 interaction, demonstrating an IC50 of less than 1 nM. This compound is significant for research in anti-tumor therapies, facilitating the study of immune checkpoint modulation and its effects on tumor growth. Its ability to effectively block PD-L1 signaling makes it a valuable tool for exploring therapeutic strategies in cancer immunotherapy. -
PD-1/PD-L1 Inhibitor
PD-1/PD-L1-IN-19 is a small-molecule inhibitor targeting the PD-1/PD-L1 protein-protein interaction. With an IC50 of 62.3 nM, it effectively inhibits the binding of PD-1 to PD-L1, thereby modulating immune responses. This compound is suitable for research applications in cancer immunotherapy, as well as studies focused on infectious and autoimmune diseases. -
PD-1/PD-L1 Inhibitor
PD-1/PD-L1-IN-17 is a potent inhibitor of the PD-1/PD-L1 interaction, with an IC50 value of 26.8 nM. This compound serves as a valuable lead in the development of PD-1/PD-L1 inhibitors, making it an important tool for cancer research. Its ability to modulate immune checkpoint pathways highlights its potential in the exploration of cancer immunotherapy strategies. -
PD-1/PD-L1 Inhibitor
HBV/HDV-IN-1 is a potent inhibitor of PD-1/PD-L1 interactions, demonstrating EC50 values of 8 nM for T cell activation and 35 nM for PD-L1 internalization. This compound is essential for investigating the role of immune checkpoint modulation in hepatitis B virus (HBV) and hepatitis D virus (HDV) infections. Its ability to enhance T cell responses makes it valuable for research in immunotherapy and viral pathogenesis. -
PD-1/PD-L1 Inhibitor
PD-1/PD-L1-IN-52 is an orally bioavailable inhibitor of the PD-1/PD-L1 interaction, demonstrating an IC50 of 109.9 nM. This compound exhibits significant antitumor effects, as evidenced by a tumor growth inhibition (TGI) of 49.6% in a C57BL/6 mouse xenograft model utilizing human PD-1-expressing MC38 colon cancer cells. Research applications include the exploration of immune checkpoint modulation and therapeutic strategies in cancer treatment. -
PD-1/PD-L1 Inhibitor
PD-1/PD-L1-IN-31 is a potent inhibitor of the PD-1/PD-L1 pathway, demonstrating an IC50 value of 2.2 nM. This compound enhances the secretion of interferon-gamma (IFN-γ) and stimulates the immune response of peripheral blood mononuclear cells (PBMCs), leading to the inhibition of tumor cell proliferation. PD-1/PD-L1-IN-31 is valuable for research applications focused on cancer immunotherapy and the modulation of immune checkpoints. -
PD-1/PD-L1 Inhibitor
PD-1-IN-25 is a potent inhibitor of the PD-1/PD-L1 interaction, exhibiting an IC50 value of 10.2 nM as determined by HTRF assay. This compound enhances CD8+ T cell activation by disrupting PD-1/PD-L1 signaling pathways. PD-1-IN-25 demonstrates significant potential for delaying tumor growth, making it a valuable tool for cancer immunotherapy research. -
PD-1/PD-L1 Inhibitor
BMS-242 is a small molecule inhibitor targeting the PD-1/PD-L1 interaction. It effectively binds to the hydrophobic channel pocket of PD-L1, disrupting the PD-1/PD-L1 immune checkpoint pathway. This action enhances anti-tumor immunity, making BMS-242 a valuable tool for cancer research and therapeutic studies focused on immune modulation. -
PD-1/PD-L1 Inhibitor
PD-1/PD-L1-IN-24 is a potent inhibitor of the PD-1/PD-L1 pathway, exhibiting an IC50 value of 1.57 nM. This compound effectively restores T-cell function by significantly increasing the levels of IFN-γ at the cellular level. With low toxicity towards peripheral blood mononuclear cells (PBMCs), PD-1/PD-L1-IN-24 is suitable for research applications focused on cancer immunotherapy and autoimmunity studies. -
PD-1/PD-L1 Inhibitor
PD-1/PD-L1-IN-21 is a small-molecule inhibitor targeting the PD-1/PD-L1 protein-protein interaction, exhibiting an IC50 of 4.99 μM. This compound effectively blocks PD-1 and PD-L1, making it a valuable tool for research into cancer, infectious diseases, and autoimmune conditions. Its ability to disrupt this immune checkpoint pathway positions PD-1/PD-L1-IN-21 as a significant reagent for studies aimed at enhancing anti-tumor immunity and understanding immune responses. -
PD-1/PD-L1 Inhibitor
PD-1/PD-L1-IN-53 is a potent inhibitor of the PD-1/PD-L1 and VISTA signaling pathways. This compound is primarily utilized in anti-cancer research to investigate immune checkpoint mechanisms and enhance T-cell activation. PD-1/PD-L1-IN-53 provides valuable insights for studies focused on tumor microenvironments and immunotherapy responses. -
PD-L1/VISTA Inhibitor
PD-L1/VISTA-IN-1 is a potent dual-target inhibitor of programmed death ligand 1 (PD-L1) and V-domain Ig suppressor of T cell activation (VISTA). This compound effectively disrupts the PD-1/PD-L1 interaction with an IC50 of 0.1492 μM and inhibits the VISTA pathway with a KD of 0.2723 μM, promoting T cell reactivation. PD-L1/VISTA-IN-1 demonstrates significant anti-tumor activity, making it a valuable tool for cancer immunotherapy research. -
PD-1/PD-L1 Inhibitor
HBV/HDV-IN-2 is a potent inhibitor of both hepatitis B virus (HBV) and hepatitis D virus (HDV), as well as the PD-1/PD-L1 pathway. It exhibits an EC50 of 35 nM for T cell activation, making it a valuable tool for investigating immune modulation in viral infections. This compound is applicable in research aimed at understanding the interplay between viral infections and immune checkpoint regulation. -
PD-1/PD-L1 Inhibitor
PD-1/PD-L1-IN-55 is a potent inhibitor targeting the PD-1/PD-L1 immune checkpoint pathway, exhibiting an IC50 of 4.8 nM. This compound enhances the secretion of IFN-γ and decreases the incidence of late apoptosis in PD-L1 expressing cells. PD-1/PD-L1-IN-55 is valuable for research applications in cancer therapy and immunology, particularly in studies aimed at restoring T-cell activation and modulating immune responses. -
PDCD1/PD-1/CD279 Antibody
Liscastobart is a humanized IgG4κ antibody that specifically targets the programmed cell death protein 1 (PDCD1/PD-1/CD279). This antibody is instrumental in studies aimed at understanding immune regulation and checkpoint inhibition, making it valuable for cancer immunotherapy research. Its application includes assessing PD-1 blockade effects in various in vitro and in vivo models. -
PD-1/PD-L1 Inhibitor
PD1-PDL1-IN 2 is a potent and selective inhibitor of the PD-1/PD-L1 pathway. This compound demonstrates significant antitumor activity in vivo by promoting cytotoxic T-cell infiltration into tumors and inducing interleukin-2 (IL-2) expression. Additionally, PD1-PDL1-IN 2 strongly inhibits the mRNA expression of TGF-β, making it a valuable tool for research in cancer immunotherapy and the modulation of immune responses. -
PD-L1 Inhibitor
PD-L1-IN-7 is a potent inhibitor of programmed cell death ligand 1 (PD-L1), effectively disrupting the PD-1/PD-L1 interaction with an IC50 of 0.2 nM. This compound facilitates the internalization and retention of PD-L1 within cells, alters glycosylation patterns, and promotes PD-L1 degradation. PD-L1-IN-7 enhances T cell infiltration and boosts T cell cytotoxic function, making it a valuable tool for developing immunotherapeutic strategies against tumors. -
PD-1/PD-L1 Inhibitor
Human PD-L1 Inhibitor III is a selective inhibitor targeting the PD-1/PD-L1 pathway, which plays a critical role in immune evasion by tumors. By blocking the interaction between programmed cell death protein 1 (PD-1) and its ligand PD-L1, this compound enhances T-cell activity, promoting anti-tumor immune responses. It is valuable for researchers investigating cancer immunotherapy and assessing therapeutic strategies aimed at modulating immune checkpoint pathways. -
PD-L1 Binding Peptide
RK-10 is a PD-L1 binding peptide that specifically targets programmed death-ligand 1 (PD-L1). This peptide can be conjugated with fluorescent dyes such as Cy5 or biotin for the detection of PD-L1 expressing tumors via flow cytometry or immunohistochemistry. RK-10 serves as a valuable tool for research applications related to non-small cell lung cancer (NSCLC), breast cancer, squamous cell carcinoma, and melanoma, facilitating studies on tumor immunology and therapeutic responses. -
PD-L1 Inhibitor
PD-L1-IN-4 is a selective inhibitor of PD-L1, demonstrating potent inhibition of the PD-1/PD-L1 interaction with an IC50 value of 1.3 nM. This compound also enhances the PD-L1 inhibitory effect on T cells, with an EC50 of 152.8 nM. PD-L1-IN-4 is suitable for studies in cancer research, particularly in the context of immunotherapy and tumor microenvironment modulation. -
PD-1/PD-L1 Inhibitor
PD-1/PD-L1-IN-27 is a potent inhibitor of the PD-1/PD-L1 pathway, demonstrating an IC50 value of 134 nM. This compound exhibits significant antitumor activity while maintaining low cytotoxicity towards T cells. Additionally, PD-1/PD-L1-IN-27 effectively activates CD8+ T cells and mitigates T cell exhaustion, making it a valuable tool for immuno-oncology research applications. -
PD-1/PD-L1 Inhibior
PD-1/PD-L1-IN-47 is a potent inhibitor of the PD-1/PD-L1 signaling pathway, selectively targeting PD-L1 under acidic conditions. This compound demonstrates significant affinity for its target while exhibiting reduced toxicity, making it a valuable tool in cancer research. PD-1/PD-L1-IN-47 is ideally suited for studies focused on tumor microenvironments and immune modulation in various cancer types. -
PD-1/PD-L1 Inhibitor
SWS1 is a d-(+)-biotin-conjugated inhibitor of PD-L1 with an IC50 of 1.8 nM. It has demonstrated significant anticancer activity by enhancing tumor-infiltrating lymphocyte populations and inducing anti-tumor effects in the B16-F10 mouse model, achieving a tumor growth inhibition rate of 66.1%. SWS1 is suitable for research applications focused on immunotherapy and tumor microenvironment studies. -
PD-1/PD-L1 Inhibitor
PD-1/PD-L1-IN-34 is a potent inhibitor of the PD-1/PD-L1 interaction, exhibiting an IC50 of 0.029 μM, and demonstrates a binding affinity towards PD-L1 with a KD of 0.1554 μM. This compound activates the immune microenvironment, showcasing significant anti-tumor activity which reinforces its potential in cancer immunotherapy research. PD-1/PD-L1-IN-34 is an invaluable tool for elucidating mechanisms of immune modulation and evaluating therapeutic strategies in oncology. -
PD-1/PD-L1 Inhibitor
PD-1/PD-L1-IN-28 is a potent inhibitor of the PD-1/PD-L1 signaling pathway, exhibiting an IC50 value of 0.744 µM. This compound demonstrates significant potential in the modulation of tumor immunity, making it a valuable reagent for cancer immunotherapy research. Its ability to disrupt immune checkpoint interactions positions PD-1/PD-L1-IN-28 as an important tool for studying immune responses in various tumor models. -
CYP51/PD-L1 Inhibitor
CYP51/PD-L1-IN-4 is a potent dual-target inhibitor of CYP51 and PD-L1, demonstrating IC50 values of 0.17 μM and 0.021 μM, respectively. This compound exhibits significant antifungal activity and is effective against drug-resistant fungal strains in vitro. CYP51/PD-L1-IN-4 is suitable for research applications focused on fungal infections and the interplay between fungal pathogens and immune checkpoint regulation. -
PD-1/PD-L1 Inhibitor
PD-1/PD-L1-IN-22 is a small-molecule inhibitor specifically targeting the PD-1/PD-L1 protein-protein interaction. With an IC50 value of 0.732 μM, it effectively disrupts this pathway, making it a valuable tool in cancer, infectious disease, and autoimmune disease research. Its ability to modulate immune responses positions PD-1/PD-L1-IN-22 as a significant compound for therapeutic development in immunooncology and related fields. -
PD-1/PD-L1 Inhibitor
PD-1/PD-L1-IN-18 is a small-molecule inhibitor that specifically targets the PD-1/PD-L1 protein-protein interaction, demonstrating an IC50 of 1.054 μM. This compound effectively blocks PD-1/PD-L1 signaling, facilitating enhanced T-cell activation and antitumor responses. It is valuable for research applications focused on immunotherapy and cancer treatment strategies.
